BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

British Journal of Ophthalmology 2006;90:1542-1547; doi:10.1136/bjo.2006.098426
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhisitkul, R B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhisitkul, R B

PERSPECTIVE

Vascular endothelial growth factor biology: clinical implications for ocular treatments

R B Bhisitkul

Correspondence to:
Correspondence to:
R B Bhisitkul
Department of Ophthalmology, Beckman Vision Center, University of California San Francisco, 10 Koret Way, K301, San Francisco, CA 94143, USA; BhisitkulR{at}vision.ucsf.edu

Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.


Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularisation; CRC, colorectal cancer; ECM extracellular matrix, ; ITV, intravitreal; mAB, monoclonal antibody; PlGF, placental growth factor; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VISION, VEGF Inhibition Study in Ocular Neovascularization




This article has been cited by other articles:


Home page
IOVSHome page
H. Ameri, G. J. Chader, J.-G. Kim, S. R. Sadda, N. A. Rao, and M. S. Humayun
The Effects of Intravitreous Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5708 - 5715.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
R. K. Campbell
Etiology and effect on outcomes of hyperglycemia in hospitalized patients
Am. J. Health Syst. Pharm., May 15, 2007; 64(10_Supplement_6): S4 - S8.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.